IMMIX BIOPHARMA INC (IMMX) Fundamental Analysis & Valuation

NASDAQ:IMMX • US45258H1068

Current stock price

8.58 USD
+0.43 (+5.28%)
At close:
8.58 USD
0 (0%)
After Hours:

This IMMX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. IMMX Profitability Analysis

1.1 Basic Checks

  • In the past year IMMX has reported negative net income.
  • In the past year IMMX has reported a negative cash flow from operations.
  • IMMX had negative earnings in each of the past 5 years.
  • In the past 5 years IMMX always reported negative operating cash flow.
IMMX Yearly Net Income VS EBIT VS OCF VS FCFIMMX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -117.34%, IMMX is doing worse than 80.08% of the companies in the same industry.
  • IMMX's Return On Equity of -285.09% is on the low side compared to the rest of the industry. IMMX is outperformed by 72.34% of its industry peers.
Industry RankSector Rank
ROA -117.34%
ROE -285.09%
ROIC N/A
ROA(3y)-75.6%
ROA(5y)-114.76%
ROE(3y)-106.56%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IMMX Yearly ROA, ROE, ROICIMMX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150 -200

1.3 Margins

  • IMMX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMMX Yearly Profit, Operating, Gross MarginsIMMX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. IMMX Health Analysis

2.1 Basic Checks

  • IMMX has more shares outstanding than it did 1 year ago.
  • IMMX has more shares outstanding than it did 5 years ago.
  • IMMX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IMMX Yearly Shares OutstandingIMMX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
IMMX Yearly Total Debt VS Total AssetsIMMX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

  • IMMX has an Altman-Z score of 11.44. This indicates that IMMX is financially healthy and has little risk of bankruptcy at the moment.
  • IMMX has a better Altman-Z score (11.44) than 83.95% of its industry peers.
  • There is no outstanding debt for IMMX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 11.44
ROIC/WACCN/A
WACCN/A
IMMX Yearly LT Debt VS Equity VS FCFIMMX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 10M -10M

2.3 Liquidity

  • IMMX has a Current Ratio of 1.53. This is a normal value and indicates that IMMX is financially healthy and should not expect problems in meeting its short term obligations.
  • IMMX has a Current ratio of 1.53. This is amonst the worse of the industry: IMMX underperforms 81.82% of its industry peers.
  • IMMX has a Quick Ratio of 1.53. This is a normal value and indicates that IMMX is financially healthy and should not expect problems in meeting its short term obligations.
  • The Quick ratio of IMMX (1.53) is worse than 79.69% of its industry peers.
Industry RankSector Rank
Current Ratio 1.53
Quick Ratio 1.53
IMMX Yearly Current Assets VS Current LiabilitesIMMX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. IMMX Growth Analysis

3.1 Past

  • IMMX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 9.31%, which is quite good.
EPS 1Y (TTM)9.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • IMMX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 27.70% yearly.
  • The Revenue is expected to grow by 187.26% on average over the next years. This is a very strong growth
EPS Next Y9.67%
EPS Next 2Y15.39%
EPS Next 3Y13.04%
EPS Next 5Y27.7%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y282.12%
Revenue Next 5Y187.26%

3.3 Evolution

IMMX Yearly Revenue VS EstimatesIMMX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M 500M
IMMX Yearly EPS VS EstimatesIMMX Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

0

4. IMMX Valuation Analysis

4.1 Price/Earnings Ratio

  • IMMX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year IMMX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMMX Price Earnings VS Forward Price EarningsIMMX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMMX Per share dataIMMX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6

4.3 Compensation for Growth

  • A more expensive valuation may be justified as IMMX's earnings are expected to grow with 13.04% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.39%
EPS Next 3Y13.04%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. IMMX Dividend Analysis

5.1 Amount

  • IMMX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IMMX Fundamentals: All Metrics, Ratios and Statistics

IMMIX BIOPHARMA INC

NASDAQ:IMMX (3/30/2026, 6:11:43 PM)

After market: 8.58 0 (0%)

8.58

+0.43 (+5.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-23
Earnings (Next)05-06
Inst Owners46.21%
Inst Owner Change707.01%
Ins Owners16.64%
Ins Owner Change0.03%
Market Cap447.45M
Revenue(TTM)N/A
Net Income(TTM)-23.56M
Analysts82.5
Price Target16.66 (94.17%)
Short Float %7.4%
Short Ratio3.46
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-29.32%
Min EPS beat(2)-34.8%
Max EPS beat(2)-23.84%
EPS beat(4)2
Avg EPS beat(4)3.67%
Min EPS beat(4)-34.8%
Max EPS beat(4)37.25%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)25.64%
PT rev (3m)36.11%
EPS NQ rev (1m)-7.59%
EPS NQ rev (3m)2.5%
EPS NY rev (1m)-3.36%
EPS NY rev (3m)13.98%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 54.14
P/tB 54.14
EV/EBITDA N/A
EPS(TTM)-0.77
EYN/A
EPS(NY)-0.5
Fwd EYN/A
FCF(TTM)-0.3
FCFYN/A
OCF(TTM)-0.28
OCFYN/A
SpS0
BVpS0.16
TBVpS0.16
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -117.34%
ROE -285.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-75.6%
ROA(5y)-114.76%
ROE(3y)-106.56%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 705.38%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.53
Quick Ratio 1.53
Altman-Z 11.44
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y9.67%
EPS Next 2Y15.39%
EPS Next 3Y13.04%
EPS Next 5Y27.7%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y282.12%
Revenue Next 5Y187.26%
EBIT growth 1Y-4.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-5.33%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-22.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-14.1%
OCF growth 3YN/A
OCF growth 5YN/A

IMMIX BIOPHARMA INC / IMMX Fundamental Analysis FAQ

What is the fundamental rating for IMMX stock?

ChartMill assigns a fundamental rating of 3 / 10 to IMMX.


What is the valuation status of IMMIX BIOPHARMA INC (IMMX) stock?

ChartMill assigns a valuation rating of 0 / 10 to IMMIX BIOPHARMA INC (IMMX). This can be considered as Overvalued.


How profitable is IMMIX BIOPHARMA INC (IMMX) stock?

IMMIX BIOPHARMA INC (IMMX) has a profitability rating of 0 / 10.